Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Oruka Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +4 vs. Q3 2023
- Shares held
- 7.48M
- +4.22M (+129.5%) vs. Q3 2023
- Total value
- $12.7M
- +$6.16M (+94.1%) vs. Q3 2023
- New holders
- 5
- 7 more added
- Sold out
- 1
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ORKA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 255 | $7.05B |
| Q1 2026 | 184 | $2.55B |
| Q4 2025 | 143 | $1.60B |
| Q3 2025 | 105 | $875.8M |
| Q2 2025 | 81 | $386.0M |
| Q1 2025 | 71 | $326.1M |
| Q4 2024 | 66 | $606.6M |
| Q3 2024 | 42 | $604.2M |
| Q2 2024 | 32 | $49.4M |
| Q1 2024 | 23 | $12.7M |
| Q4 2023 | 25 | $12.7M |
| Q3 2023 | 21 | $6.55M |
| Q2 2023 | 23 | $5.75M |
| Q1 2023 | 26 | $5.02M |
| Q4 2022 | 22 | $6.19M |
| Q3 2022 | 25 | $4.58M |
| Q2 2022 | 24 | $4.17M |
| Q1 2022 | 22 | $2.60M |
| Q4 2021 | 21 | $2.41M |
| Q3 2021 | 19 | $4.53M |
| Q2 2021 | 17 | $4.16M |
| Q1 2021 | 17 | $3.20M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Oruka Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cable Car Capital LLC | 4,000,452 | $6.80M | 7.12% | +4,000,452 | New |
| Western Standard LLC | 1,410,143 | $2.40M | 2.26% | +235,873+20.1% | Added |
| BML Capital Management, LLC | 706,930 | $1.20M | 0.95% | 00.0% | Unchanged |
| Vanguard Group Inc | 453,598 | $771.1K | 0.00% | +3,063+0.7% | Added |
| Newtyn Management, LLC | 269,320 | $457.8K | 0.09% | −30,680−10.2% | Reduced |
| BlackRock Inc. | 231,911 | $394.2K | 0.00% | −480.0% | Reduced |
| Geode Capital Management, LLC | 142,349 | $242.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 71,137 | $120.9K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 57,299 | $97.0K | 0.00% | +6,499+12.8% | Added |
| Dimensional Fund Advisors LP | 42,514 | $72.3K | 0.00% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 32,461 | $55.2K | 0.00% | +32,461 | New |
| Northern Trust Corp | 20,982 | $35.7K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 14,988 | $25.5K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 12,119 | $20.6K | 0.00% | +12,119 | New |
| Citadel Advisors LLC | 6,320 | $10.7K | 0.00% | +6,320 | New |
| Tower Research Capital LLC (TRC) | 3,023 | $5.14K | 0.00% | −668−18.1% | Reduced |
| UBS Group AG | 1,131 | $1.92K | 0.00% | +1,006+804.8% | Added |
| Parallel Advisors, LLC | 244 | $415 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 79 | $134 | 0.00% | +4+5.3% | Added |
| Advisor Group Holdings, Inc. | 55 | $93 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 50 | $85 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 43 | $73 | 0.00% | +12+38.7% | Added |
| JPMorgan Chase & Co | 16 | $27 | 0.00% | +4+33.3% | Added |
| Royal Bank of Canada | 56 | $0 | 0.00% | −7−11.1% | Reduced |
| Simplex Trading, LLC | 100 | $0 | 0.00% | +100 | New |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −46,948−100.0% | Sold out |